Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081384 | 0.65 | HTR2A (0.32) | — | |
| SCHEMBL8366209 | 0.65 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL9821528 | 0.63 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL16163535 | 0.63 | SLC6A2 (0.33) | CYP19A1 | |
| SCHEMBL18534201 | 0.61 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL19803952 | 0.61 | CYP19A1 (0.41) | CYP19A1 | |
| SCHEMBL20899511 | 0.60 | HCAR2 (0.34) | HCAR3HCAR2 | |
| SCHEMBL1754251 | 0.59 | — | — | |
| SCHEMBL9033178 | 0.59 | HCAR3 (0.31) | HCAR3HCAR2 | |
| SCHEMBL3341310 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1542798-A2 | PROCESS FOR THE HYDROFORMYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND USING A BIDENTATE DIPHOSPHINE COMPOSITION WITH A BRIDGING GROUP COMPRISING SP2 HYBRIDIZED CARBON ATOMS BOUND TO THE PHOSPHOROUS ATOMS | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004028689-A2 | PROCESS FOR THE HYDROFORMYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND USING A BIDENTATE DIPHOSPHINE COMPOSITION WITH A BRIDGING GROUP COMPRISING SP2 HYBRIDIZED CARBON ATOMS BOUND TO THE PHOSPHOROUS ATOMS | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | CYP19A1 1075/4885HCAR3 418/4885HCAR2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.